See a complete PubMed list of publications by Hyung Lae Kim, MD.

Selected Key Publications

Wang Y, Sparwasser T, Figlin R, Kim HL. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res. 2014;74(8):2217-2228.

Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim HL, Griffiths D, Bhowmick N, Chung L, Gandellini P, et al. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle. 2013;12(22):3526-3536.

Li P, Grigorenko E, Funari V, Enright E, Zhang H, Kim HL. Evaluation of a high-throughput, microfluidics platform for performing Taqman™ qPCR using formalin-fixed paraffin embedded tumors. Bioanalysis. 2013;5(13):1623-1633.

Zhang H, Berel D, Wang Y, Figlin RA, Kim HL. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLOS One. 2013;8(1):e54918.

Underwood W, Kim HL. Intermediate-term oncologic efficacy of laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. BJU Int. 2012;109(2):281-285.;jsessionid=2DE98B8A2A1F5728BE1B0C279A18E0AD.f04t02.

Hayn MH, Schwaab T, Underwood W, Kim HL. RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. BJU Int. 2011;108(6):876-881.

Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer. 2011;104(4):643-652.

Glenn ST, Head KL, Teh BT, Gross KW, Kim HL. Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J Biomol Screen. 2010;15(1):80-85.

Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding G, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859-864.

Yi H, Yu X, Gao P, Wang Y, Kim HL, Subjeck JR, Wang XY. Pattern recognition scavenger receptor SRA/CD204 down-regulates TLR4 signaling dependent CD8 T-cell activation. Blood. 2009;113(23):5819-5828.

Wang Y, Wang XY, Subjeck J, Kim HL. Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Mol Cancer Ther. 2008;7(12):3867-3877.

Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother. 2007;56(7):1097-1105.

Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, Kim HL. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. BioTechniques. 2007;43(5):639-647.

Kim HL, Seligson D, Liu X, Janzen N, Bui M, Yu H, Tao S, Figlin RA, Horvath S, Belldegrun AS. Using tumor markers to predict the survival of patients with metastatic renal cell carcainoma. J Urol. 2005;173(5):1496-1501.

Kim HL, Seligson D, Liu X, Janzen N, Bui M, Yu H, Tao S, Figlin RA, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10(16):5464-5471.

Kim HL, Griend Vander DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001;61(7):2833-2837.